<table>
<thead>
<tr>
<th>Nr Book</th>
<th>Abstract Title</th>
<th>Presenter</th>
<th>City</th>
<th>Country</th>
<th>OUTCOME</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IMMUNOTHERAPY COMES OF AGE TO TREAT LYMPHOMAS</td>
<td>Levy, Ronald</td>
<td>Stanford, CA</td>
<td>USA</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>GENETIC SIGNATURES AND TARGETABLE PATHWAYS IN LYMPHOID MALIGNANCIES</td>
<td>Shipp, Margaret</td>
<td>Boston, MA</td>
<td>USA</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>GENOMES IN TRANSIT: WHAT MULTI-OmICS CAN TELL US ON LYMPHOMAS</td>
<td>Siebert, Reiner</td>
<td>Ulm</td>
<td>Germany</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZETEMOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA</td>
<td>Morschauser, Franck</td>
<td>Lille</td>
<td>France</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>CD38-Passenger genetic screens uncover a B cell receptor-MYD088 superpathway in diffuse large B cell lymphoma</td>
<td>Young, Ryan</td>
<td>Bethesda, Maryland</td>
<td>USA</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>BENDAMUSTINE (B), FOLLOWED BY OBNIFLUMAB (G) AND VENETOGLA (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)</td>
<td>Cramer, Paula</td>
<td>Cologne</td>
<td>Germany</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS</td>
<td>Schuster, Stephen</td>
<td>Philadelphia</td>
<td>USA</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL): primary results of the pivotal trial ZUMA-1</td>
<td>Neelapu, Sattva</td>
<td>Houston</td>
<td>USA</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM MALIGNANT MELANOMA?</td>
<td>Eggermont, Alexander</td>
<td>Villejuif</td>
<td>France</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM LUNG CANCER?</td>
<td>Stahel, Rolf</td>
<td>Zurich</td>
<td>Switzerland</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Outcome of curative radiotherapy for localised follicular lymphoma in the era of 18F-FDG PET-CT staging: an international collaborative study on behalf of IROG</td>
<td>Brady, Jessica</td>
<td>London</td>
<td>UK</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>CVP or R-CVP given after involved-field radiotherapy improves progression free survival in stage I-II follicular lymphoma: Results of an International Randomized Trial</td>
<td>MacManus, Michael</td>
<td>Melbourne</td>
<td>Australia</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Rituximab maintenance versus observation after immunochemotherapy (R-CHOP, R-MCP, R-FCM) in previously untreated follicular lymphoma: a randomised trial of GLSG and OSHG</td>
<td>Hoster, Eva</td>
<td>München</td>
<td>Germany</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Long term results of the FOL105 randomized study comparing R-CVP with R-CHOP and R-FM as first line therapy in patients with advanced stage Follicular Lymphoma. A FIL study.</td>
<td>Luminari, Stefano</td>
<td>Reggio Emilia</td>
<td>Italy</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Cause of death in follicular lymphoma in the rituximab era: a pooled analysis of French and US cohorts.</td>
<td>Sarzky, Clémentine</td>
<td>Pierre Bénite</td>
<td>France</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Prognostic value of baseline total metabolic tumor volume (MTTV) for patients with early stage Hodgkin lymphoma enrolled in the standard arm of the H10 (EORTC/LYSA/FIL) trial.</td>
<td>COTTEREAU, Anne-Ségolène</td>
<td>PARIS</td>
<td>France</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented IICE</td>
<td>Moskowitz, Alison</td>
<td>New York</td>
<td>USA</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Can baseline PET-CT features predict outcomes in advanced Hodgkin Lymphoma?</td>
<td>Pike, Lucy</td>
<td>London</td>
<td>UK</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL)</td>
<td>Rigacci, Luigi</td>
<td>Florence</td>
<td>Italy</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Prognostic value of PET-CT after first-line immunotherapy for follicular lymphoma in the Phase III GALLIUM study</td>
<td>Trotman, Judith</td>
<td>Sydney</td>
<td>Australia</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>FDG-PET as a biomarker of response in DLBCL: The HOVON 84 study experience</td>
<td>Burggraaf, Coreline</td>
<td>Amsterdam</td>
<td>Netherlands</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Non-medistrial cases of grey zone lymphoma: a pathological and clinical series of 17 cases from the LYSA.</td>
<td>Sarzky, Clémentine</td>
<td>Pierre Bénite</td>
<td>France</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>FOXP1 expression is inversely correlated with EZH2 mutation status and predicts poor failure-free survival in follicular lymphoma treated with rituximab and chemotherapy</td>
<td>Mottok, Anja</td>
<td>Vancouver</td>
<td>Canada</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Elevated expression of LAG3 is associated with poor outcome in patients with DLBCL treated with R-CHOP.</td>
<td>Keane, Colm</td>
<td>Woolloongabba</td>
<td>Australia</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Cell of origin combined with CNS International Prognostic Index improves identification of DLBCL patients with high CNS relapse risk after initial immunotherapy</td>
<td>Klanova, Magdalena</td>
<td>Basel</td>
<td>Switzerland</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>NLK46 expression is a diagnostic and prognostic biomarker in primary gastrointestinal T-cell lymphoproliferations. A CELAC network study.</td>
<td>Cheminant, Morgane</td>
<td>Paris</td>
<td>France</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Adult Patients with CSBVI-like Features: A Distinct Subtype of Epstein-Barr Virus positive T/NK-cell Lymphoproliferative Disorder</td>
<td>Kawamoto, Keisuke</td>
<td>Kureme</td>
<td>Japan</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>PHARMACOLOGICAL ACTIVITY OF CB-103 IN HAEMATOLOGICAL MALIGNANCIES – AN ORAL pan-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION</td>
<td>Weber, Dirk</td>
<td>Basel</td>
<td>Switzerland</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Anti-tumor activity of daratumab, a novel human CD38 monoclonal antibody, in in vitro and in vivo models of B-cell Non-Hodgkin Lymphoma</td>
<td>Pérez-Galán, Patricia</td>
<td>Barcelona</td>
<td>Spain</td>
<td>oral</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>A new BCL-2 inhibitor (SS5746/BCL201) as monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: Preliminary results of the first-in-human study</td>
<td>Le Gouill, Steven</td>
<td>Nantes</td>
<td>France</td>
<td>oral</td>
<td></td>
</tr>
</tbody>
</table>
Sawas, Ahmed
New York
USA
oral

First Clinical Results of ADCT-402, a Novel Pyrrolidinobenzodiazepine-Based Antibody Drug Conjugate (ADC), in Relapsed/Refractory B-cell Lineage NHL.
Kuhl, Brad
St. Louis
USA
oral

Final results of CALGB 50803 (Alliance): A Phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.
Martin, Peter
New York
USA
oral

L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) – a single-arm phase II study.
Salles, Gilles
Pierre Bénite
France
oral

A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Follicular B-Cell Lymphoma.
Morschhauser, Franck
Lille
France
oral

Phase Ib study of CC-122 in combination with obinutuzumab (GA101): relapsed or refractory (R/R) patients with B-cell non-Hodgkin lymphoma (NHL).
Michot, Jean
Villejuif
France
oral

Phase I/II dose escalation and expansion of ibritumotab and bifilarsib in rituximab-refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.
Batlevs, Connie
New York
USA
oral

Updated Results of a Multicenter Phase I/Ib Study of TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory MCL or CLL.
Davidis, Matthew
Boston
USA
oral

GI Viruse-C (GBV-C) Infection and Risk of Lymphoma: a Case-Control Study from North America.
Fama, Angelo
Rochester
USA
oral

Drug Perturbation Based Stratification of Lymphoproliferative Disorders.
Dietrich, Sascha
Heidelberg
Germany
oral

ETSI positively regulates FAIM3 in activated B cell-like (ABC) diffuse large B-cell lymphoma (DLBCL).
Priebe, Valdemar
Bellinzona
Switzerland
oral

NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPOPHIN-1 AND RIBOSOME ASSOCIATED COMPONENTS.
Pozzo, Federico
Aviano
Italy
oral

Activation of RHOA-AV1 signaling in angioimmunoblastic T-cell lymphoma.
Sakata-Yanagimoto, Mamiko
Ibaraki
Japan
oral

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.
Bodddicker, Rebecca
Rochester, MN
USA
oral

Molecular classification of primary mediastinal large B cell lymphoma using formalin-fixed, paraffin-embedded tissue specimens – an LLMP project.
Motoki, Anja
Vancouver
Canada
oral

Metabolic Heterogeneity on Baseline 18-FDG PET-CT Scan Predicts Outcome in Primary Mediastinal B-Cell Lymphoma.
Cariani, Luca
Bellinzona
Switzerland
oral

Outcomes of Adults, Adolescents, and Children with Primary Mediastinal B-Cell Lymphoma Treated with Dose-Adjusted EPOCH-R Therapy: A Multicenter Retrospective Analysis.
Roth, Lisa
New York
USA
oral

Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rPMBCL); interim analysis of the KEYNOTE-170 phase 2 trial.
Zinzani, Pier Luigi
Bologna
Italy
oral

Restore & Target: A conceptually novel treatment approach to classical Hodgkin’s lymphoma.
Schmitt, Clemens
Berlin
Germany
oral

GENOTYPING OF CLASSICAL HODGKIN LYMPHOMA ON THE LIQUID BIOPSY.
Bruscaggin, Alessio
Bellinzona
Switzerland
oral

bBEACOPP with or without Rituximab in Interim-PET-Positive Advanced-Stage Hodgkin Lymphoma: Updated Results of the International, Randomized Phase 3 GHSG HD18 Trial.
Borchmann, Peter
Cologne
Germany
oral

Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: longer follow up confirms efficacy of de-escalation after a negative interim PET scan (CRUK/07/03A).
Trotman, Judith
Concord
Australia
oral

Blockade of the PD-1 checkpoint with anti-PD-L1 antibody avelumab is sufficient for clinical activity in relapsed/refractory classical Hodgkin lymphoma.
Chen, Robert
Duarte
USA
oral

Aleman, Berthe
Amsterdam
Netherlands
oral

Clinical outcomes and molecular characterization from a phase II study of copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma.
Lenz, Georg
Münster
Germany
oral

DYNAMO: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma Malignancies.
Zinzani, Pier Luigi
Bologna
Italy
oral

Bruton’s tyrosine kinase (BTK) inhibitor BGB-3112 demonstrates high very good partial response (VGPR) rate in patients with Waldenstrom macroglobulinemia (WM).
Trotman, Judith
Concord
Australia
oral

Ibritumotab in Relapse or Refractory Primary CNS and Vitreo-Retinal Lymphoma. Results of the primary end-point of the iLOC phase II study from the LYSA and the French LOC network.
Soussain, Carole
Saint-Cloud
France
oral

TAK-659, an investigational reversible dual SYK/FLT3 inhibitor, in patients with lymphoma: Updated results from dose-escalation and expansion cohorts of a phase 1 study.
Kaplan, Jason
Chicago
USA
oral

The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B-Cell Malignancies.
Hamlin, Paul
Basking Ridge, NJ
USA
oral

Gene expression profiling using a RTMLPA assay allows for an accurate classification of peripheral T-cell lymphoma and highlights novel subgroups within PTCLs-NOS.
Ruminy, Philippe
Rouen
France
oral

CHOP versus GEM-P in the first-line treatment of T-cell lymphoma: initial results of the UK NCRI phase II randomised CHEMO-T trial.
Gieseon, Mary
Sutton
UK
oral

Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma: A propensity score matching analysis of patients from LYSA centers.
Fossard, Gaelle
Pierre Bénite
France
oral

Brentuximab Vedotin vs Physician’s Choice in CTCL Patients from the Phase 3 ALCANZA study: Analysis of Outcomes by CD30 Expression.
Kim, Youn
Stanford
USA
oral
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>67</td>
<td>Improved survival outcomes for patients with extra-nodal NK/T lymphoma; data from 140 patients prospectively registered in the International T-Cell Project</td>
<td>Fox, Christopher</td>
<td>Nottingham, UK</td>
<td>oral</td>
</tr>
<tr>
<td>68</td>
<td>GAD-M regimen for newly diagnosed extranodal NK/T cell lymphoma: analysis of efficacy and safety from Phase II Study (NCT 01991158)</td>
<td>Li, Z.</td>
<td>Guangzhou, China</td>
<td>oral</td>
</tr>
<tr>
<td>69</td>
<td>Results of a phase II study of brentuximab vedotin in the first line treatment of Hodgkin lymphoma patients considered unsuitable for standard chemotherapy (BREVIITY)</td>
<td>Gibb, Adam</td>
<td>Manchester, UK</td>
<td>oral</td>
</tr>
<tr>
<td>70</td>
<td>Brentuximab Vedotin Consolidation to Reduce Radiation Use in Patients with Limited Stage Non-bulky Hodgkin Lymphoma: An Update from a Phase 2 Clinical Trial</td>
<td>Park, Steven</td>
<td>Charlotte, USA</td>
<td>oral</td>
</tr>
<tr>
<td>71</td>
<td>Results of a multicentre UK-wide study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the pre-transplant naive setting</td>
<td>Eyre, Toby</td>
<td>Oxford, UK</td>
<td>oral</td>
</tr>
<tr>
<td>73</td>
<td>Safety and Efficacy of Combination of Brentuximab Vedotin and Nivolumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group [E4412]</td>
<td>Diefenbach, Catherine</td>
<td>New York, USA</td>
<td>oral</td>
</tr>
<tr>
<td>74</td>
<td>Interim results from a phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma</td>
<td>Herrera, Alex</td>
<td>Otsu, USA</td>
<td>oral</td>
</tr>
<tr>
<td>75</td>
<td>CLARITHROMYCIN AS A &quot;REPURPOSING DRUG&quot; AGAINST LYMPHOMAS: SAFETY AND EFFICACY PROFILES IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL)</td>
<td>Ferreri, André</td>
<td>Milano, Italy</td>
<td>oral</td>
</tr>
<tr>
<td>76</td>
<td>A Phase 1 Study of Prolaktirexe Plus Romidepsin Reveals Marked Activity in Patients with Relapsed or Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)</td>
<td>Amengual, Jennifer</td>
<td>New York, USA</td>
<td>oral</td>
</tr>
<tr>
<td>77</td>
<td>Canadian Cancer Trials Group (CCTG) LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant (ASCT) in relapsed/refractory diffuse large B cell lymphoma (RR-DLBCL) - Outcome of Ibrutinib + R-GDP</td>
<td>Kuruvilla, John</td>
<td>Kingston, Canada</td>
<td>oral</td>
</tr>
<tr>
<td>78</td>
<td>EFFECT OF ADDING IDELALISIB TO FRONTLINE OFatumumab PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL.</td>
<td>Pettitt, Andrew</td>
<td>Liverpool, UK</td>
<td>oral</td>
</tr>
<tr>
<td>79</td>
<td>Venetoclax (VEN), Bendamustine (B) and Rituximab (R) in Patients (Pts) with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Final Results of a Phase I Study</td>
<td>Swinnen, Lode</td>
<td>Baltimore, USA</td>
<td>oral</td>
</tr>
<tr>
<td>80</td>
<td>Polo-R-CHP: polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, prednisone for patients with previously untreated diffuse large B-cell lymphoma</td>
<td>Tilly, Hervé</td>
<td>Rouen, France</td>
<td>oral</td>
</tr>
<tr>
<td>81</td>
<td>Application of a gene expression-based model in combination with FDG-PET imaging to predict treatment response in advanced Hodgkin lymphoma in the RATHL study (CRUK/07/033)</td>
<td>Burton, Cathy</td>
<td>Leeds, UK</td>
<td>oral</td>
</tr>
<tr>
<td>82</td>
<td>The 23-gene expression-based assay does not predict interim PET scan results after ABVD in advanced stage classical Hodgkin lymphoma in the US Intergroup 50816 trial.</td>
<td>Scott, David</td>
<td>Vancouver, Canada</td>
<td>oral</td>
</tr>
<tr>
<td>83</td>
<td>Gene mutations and copy number alterations (CNA) predict for early failure in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP</td>
<td>Glouhy, Ivan</td>
<td>Barcelona, Spain</td>
<td>oral</td>
</tr>
<tr>
<td>84</td>
<td>KM2T2D AND TP53 MUTATIONS PREDICT POOR FPS AND OS IN MANTEL CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL</td>
<td>Ferrero, Simone</td>
<td>Torino, Italy</td>
<td>oral</td>
</tr>
<tr>
<td>85</td>
<td>Baseline circulating cell-free DNA load is related to, but adds prognostic value to metabolic tumor burden measured by FDG PET/CT in follicular lymphoma</td>
<td>Delfau-Larue, Marie</td>
<td>CRETEIL, France</td>
<td>oral</td>
</tr>
<tr>
<td>86</td>
<td>Evaluation of clinogenic risk models for outcome of follicular lymphoma patients in the PRIMA trial</td>
<td>Huet, Sarah</td>
<td>Pierre-Bénite, France</td>
<td>oral</td>
</tr>
<tr>
<td>OT01</td>
<td>ROBUST: Phase III Randomized Study of Lenalidomide/R-CHOP vs Placebo/R-CHOP in Untreated ABC-Type Diffuse Large B-cell Lymphoma and Feasibility of Cell of Origin Subtyping</td>
<td>Chiappella, Annalisa</td>
<td>Torino, Italy</td>
<td>oral</td>
</tr>
<tr>
<td>OT02</td>
<td>Phase II study of durvalumab (anti-PD-L1) combined with either R-CHOP or lenalidomide and R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma</td>
<td>Jaeger, Ulrich</td>
<td>Vienna, Austria</td>
<td>oral</td>
</tr>
<tr>
<td>OT03</td>
<td>CheckMate 647: A Phase 2, Open-Label Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma or Relapsed/Refractory Primary Testicular Lymphoma</td>
<td>Nayak, Lakshmi</td>
<td>Boston, USA</td>
<td>oral</td>
</tr>
<tr>
<td>OT04</td>
<td>MCL-R2 ELDERLY: A PHASE III STUDY of the European MCL network ASSESSING Efficacy of alternating immunotherapy (R-CHOP / R-HAD) and a rituximab-lenalidomide maintenance</td>
<td>Ribrag, Vincent</td>
<td>Villejuif, France</td>
<td>oral</td>
</tr>
<tr>
<td>OT05</td>
<td>Title: Phase 3 Study of Ibrutinib in Combination With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)</td>
<td>Tam, Constantine</td>
<td>Melbourne, Australia</td>
<td>oral</td>
</tr>
<tr>
<td>OT06</td>
<td>A head-to-head phase 3 study comparing BGB-3111 and ibrutinib in patients with Waldenstrom macroglobulinaemia</td>
<td>Buske, Christian</td>
<td>Ulm, Germany</td>
<td>oral</td>
</tr>
<tr>
<td>87</td>
<td>Higher Age is Associated with Increased Mutational Burden but does Not Impact Treatment Efficacy in Follicular Lymphoma</td>
<td>Ali, Stefan</td>
<td>Munich, Germany</td>
<td>oral</td>
</tr>
<tr>
<td>88</td>
<td>Low NK cell count at diagnosis is associated with shorter PFS in elderly patients with DLBCL treated with RCHOP and randomized for Lenalidomide maintenance. A LYSA Study</td>
<td>DELFAU-LARUE, Marie</td>
<td>CRETEIL, France</td>
<td>oral</td>
</tr>
</tbody>
</table>
124 CD27 stimulation enhances CD20 mAb therapy through activation of innate immunity
Lim, Sean
Southampton, UK
oral
125 Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Autologous Transplant: Full Results After Extended Follow-Up of the Phase 2 CheckMate 205 Trial
Fanale, Michelle
Houston, USA
oral
126 Pembrolizumab Monotherapy in Patients With Primary Refractory Classical Hodgkin Lymphoma: Subgroup Analysis of the Phase 2 KEYNOTE-087 Study
Zinzani, Pier Luigi
Bologna, Italy
oral
127 A Phase Ib Study Evaluating the Safety and Clinical Activity of Atezolizumab Combined With Obinutuzumab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Palmiba, M.
New York, NY
oral
128 High CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSEND NHL 002)
Abramson, Jeremy
Boston, USA
oral
129 A Phase I Trial of 19-28z CAR-T cells Post-High Dose Therapy and Autologous Transplantation (HDT-ASCT) for Relapsed and Refractory (r/r) B-cell non-Hodgkin Lymphoma (B-NHL)
Sauter, Craig
New York, NY
oral
130 PFS but not SOX11 IHC has prognostic value independent of MIPI and Ki-67 in prospective trials of the European-MCL Network
Aukema, Neetje
Kiel, Germany
oral
131 First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: results of the BRIGHT 5-year follow-up study
Flinn, Ian
Nashville, Tennessee, USA
oral
132 First line treatment by the RbVD regimen elicits high clinical and molecular response rates and prolonged survival in elderly MCL patients; final results of a LYSAl group trial
Gressin, Remy
GRENOBLE, France
oral
133 Ibrutinib-Ruxitumab Followed by Reduced Chemo-immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: a Window of Opportunity to Reduce Chemo
Wang, Michael
Houston, USA
oral
134 Ibrutinib vs Temsirolimus: Three-year Follow-up of Patients With Previously Treated Mantle Cell Lymphoma from the Phase 3, International, Randomized, Open-Label RAY Study
Rue, Simon
Plymouth, UK
oral
135 Combination Ibrutinib (ibr) and Venetoclax (Ven) for the Treatment of Mantle Cell Lymphoma (MCL): Primary Endpoint Assessment of the Phase 2 AIM Study
Tam, Constantine
Melbourne, Australia
oral
136 Interferon-Free Antiviral Treatment in B-cell Lymphoproliferative Disorders associated with Chronic Hepatitis-C Virus Infection
Friigen, Marco
Pavia, Italy
oral
137 Immunochemotherapy with obinutuzumab or ruxitumab in a subset of patients in the randomised GALLIUM trial with previously untreated marginal zone lymphoma (MZL)
Herold, Michael
Erfurt, Germany
oral
138 Long-term results of the Multicenter Phase II Trial with Bendamustine and Ruxitumab as First Line Treatment for Patients with MALT Lymphoma (MALT-008-01)
Salar, Antonio
Barcelona, Spain
oral
139 Phase IIb study of lenalidomide plus ruxitumab followed by maintenance in relapsed or refractory NHL: analysis of marginal zone lymphoma
Coleman, Morton
New York, NY, USA
oral
140 Whole-exome-sequencing of nodal marginal zone lymphomas identifies recurrent molecular lesions in genes involved in chromatin remodelling and NOTCH signalling
Pillonel, Vincent
Basel, Switzerland
poster, Pathology
141 Integrative mutational analysis of Pediatric-Type Follicular Lymphoma reveals TNRFSF14 and MAP2K1 as the most frequently mutated genes
Schmidt, Janine
Tübingen, Germany
poster, Pathology
142 Down-regulation of mir-150 and up-regulation of its target FOXP1 is associated with transformation of follicular lymphoma
Musilova, Katerina
Brno, Czech Republic
poster, Pathology
143 NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY
Ferrero, Simone
Torino, Italy
poster, Pathology
144 Host Genetic Variation in the TNF and NF-kB Pathways and Prognosis in Mantle Cell Lymphoma: An Analysis of Two Studies
Wang, Yucai
Rochester, USA
poster, Pathology
145 High proliferation (MCL3 assay) is associated with inferior outcomes in patients treated with intensive regimens - a correlative study from the CALGB 50403 (Alliance) trial
Scott, David
Vancouver, Canada
poster, Pathology
146 IET5I phosphorylation at Thr38 (pET5I) is associated with cell of origin (COO), cell cycle activation, and inferior outcome in diffuse large B cell lymphoma (DLBCL)
Chung, Elaine
Bellinzona, Switzerland
poster, Pathology
147 DNM3-A 2 expression levels characterise diffuse large B-cell lymphoma with distinct methylation patterns and outcome
Kuhl, Andrea
London, UK
poster, Pathology
148 Kras and Ago2 interaction promote initiation of plasmablastic lymphoma using an in vivo mouse transplant model
Thai, Kevin
Cambridge, USA
poster, Pathology
149 Comprehensive epigenetic and transcriptional survey of the "imprintome" in normal B-cells and germinai center derived B-cell lymphomas of the MM6L and ICGC MM6L-Seq networks
Bens, Susanne
Ulm, Germany
poster, Pathology
150 Gene expression profiling and mutation analysis can aid treatment decision making in aggressive B cell lymphoma patients
Burton, Cathy
Leeds, UK
poster, Pathology
151 Application of cell-of-origin subtypes determined by digital gene expression in HIV-related diffuse large B-cell lymphomas
Baptista, Marie-Joao
Badalona, Spain
poster, Pathology
152 BIOCLL14: THE PROGNOSTIC ROLE OF CELL OF ORIGIN PROFILE, MYC, BCL2 AND TP53 IN UNTREATED POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA.
Chiappella, Annalisa
Torino, Italy
poster, Pathology
153 Prognostic significance and correlation to gene expression profile of EZH2 mutations in diffuse large B-cell lymphoma (DLBCL) in two large prospective studies
Cummin, Thomas
Southampton, UK
poster, Pathology
154 Preliminary evidence of a molecular predictor of tazemetostat response, beyond EZH2 mutation, in NHL patients via characterization of archival tumor and circulating tumor DNA
Blakemore, Stephen
Cambridge, USA
poster, Pathology
155 Array-based DNA methylation analyses of primary lymphomas of the central nervous system
Vegt, Julia
Ulm, Germany
poster, Pathology
221
R-CHOP/R-HDAC and rituximab maintenance results in high complete remission rate, minimal residual disease negativity, and excellent survival in elderly MCL patients. Klenzer, Pavel Prague 2 Czech Republic poster Manet Cell Lymphoma
209 Maintenance rituximab improves survival in newly diagnosed mantle cell lymphoma patients: analysis of the Czech Lymphoma Study Group Obr, Aleš Olomouc Czech Republic poster Manet Cell Lymphoma
211 SAKK 16/13 - Ibrutinib and bortezomib followed by ibrutinib maintenance in patients with relapsed and refractory mantle cell lymphoma: Phase I report of a Phase I/II trial Novak, Urban Bern Switzerland poster Manet Cell Lymphoma
212 Phase I/II clinical trial of an activated whole tumor cell vaccine followed by transfer of immune T cells in patients with mantle cell lymphoma. Frank, Matthew Stanford USA poster Manet Cell Lymphoma
213 Obinutuzumab plus ibrutinib in relapse/refractory mantle cell lymphoma patients: results of the Oasis phase II trial. Le Gouill, Steven Nantes France poster Manet Cell Lymphoma
214 Rituximab maintenance after autologous stem cell transplantation in patients with mantle cell lymphoma, final result of the LyMa trial conducted on behalf of the LySa group Le Gouill, Steven Nantes France poster Manet Cell Lymphoma
215 Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study Fowler, Nathan Houston USA poster Indolent Lymphoma
216 Safety and efficacy of single-agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): a multicenter, open-label, phase 2 study Collins, Graham Oxford UK poster Indolent Lymphoma
217 Progression-free survival following lenalidomide-based treatment is significantly longer in extragastroin than in gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) Kiesewetter, Barbara Vienna Austria poster Indolent Lymphoma
218 Beyond Maximum Grade: A Novel, Longitudinal Toxicity Over Time (ToxT) Adverse Event Analysis of Lenalidomide in Follicular Lymphoma in CALGB 50601 (Alliance) Thanarajasingam, Gita Rochester USA poster Indolent Lymphoma
219 Treatment with combination of lenalidomide and rituximab achieves durable responses in a long term follow up of patients with indolent non- Hodgkin's lymphoma Chaudhry, Maria Houston USA poster Indolent Lymphoma
220 Minimal residual disease and outcomes in relapsed/refractory follicular lymphoma (FL) in the Phase III GADOLIN trial of obinutuzumab and bendamustine vs bendamustine Pott, Christiane Kiel Germany poster Indolent Lymphoma
221 R-CP chemotherapy in patients with IgM paraproteinaemic neuropathy produces improvements in functional, electrophysiological and serological outcomes. Duncombe, Andrew Southampton UK poster Indolent Lymphoma
222 Bendamustine-rituximab (BR) versus R-CHOP as upfront therapy for indolent B-cell lymphomas: a comparative, population-based analysis Olziewski, Adam Providence USA poster Indolent Lymphoma

221
R-CP chemoimmunotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma – Report of the prospective, multicenter Phase II STORM Trial Witzans-Harg, Mathias Heidelberg Germany poster Aggressive Lymphomas
219 Bendamustine as part of conditioning regimen for autologous stem cell transplantation in patients with aggressive lymphomas: Final analysis of a phase 2 study from GELTAMO Martin, Alejandro Salamanca Spain poster Aggressive Lymphomas
215 Reduced intensity (FB2) vs reduced toxicity myeloablative (FB3-4) Fludarabine/busulfan based conditioning regimens for non-Hodgkin lymphoma (NHL) allografted patients. Le Bourgeois, Amandine Nantes France poster Aggressive Lymphomas
214 Venetoclax (VEN) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): Long Term Follow-Up Update for Patients Enrolled in ECOG 1405 center retrospective study. Chin, Collin Nedlands Australia poster Aggressive Lymphomas
213 Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DBLCL undergoing R-CHOP immunomunotherapy Murawski, Niels Hamburg Germany poster Aggressive Lymphomas
212 Current therapy of secondary CNS involvement in malignant lymphoma: Data from a multicenter prospective international registry Korfel, Agnieszka Berlin Germany poster Aggressive Lymphomas
211 Validation of the CNS International Prognostic Index in a Large Asian Cohort – Data from the Singapore Lymphoma Study Group Lee, Yuh Shan Singapore Singapore poster Aggressive Lymphomas
210 The 5-year follow-up results of the CSR protocol with rituximab and intrathecal liposomal cytarabine for Primary CNS Lymphoma: a prospective phase 2 study of the LYSA. GHESQUIERES, Herve Pierre Benite France poster Aggressive Lymphomas
208 Dose-dense chemoimmunotherapy and CNS prophylaxis in patients with high-risk DLBCL: a comparison of Nordic CRY-04 and CHIC studies. Leppa, Sirpa Helsinki Finland poster Aggressive Lymphomas
207 Beyond Maximum Grade: A Novel, Longitudinal Toxicity Over Time (ToxT) Adverse Event Analysis of Lenalidomide in Follicular Lymphoma in CALGB 50601 (Alliance) Thanarajasingam, Gita Rochester USA poster Indolent Lymphoma
206 Maintenance of lenalidomide and bortezomib in relapse/refractory mantle cell lymphoma patients: first results of the Oasis phase II trial. Le Gouill, Steven Nantes France poster Manet Cell Lymphoma
205 Double-expressor lymphomas do not have inferior outcome after autologous stem cell transplant in the first line treatment. Treny, Marek Praha Czech Republic poster Aggressive Lymphomas
204 Minimal residual disease and outcomes in relapsed/refractory follicular lymphoma (FL) in the Phase III GADOLIN trial of obinutuzumab and bendamustine vs bendamustine Pott, Christiane Kiel Germany poster Indolent Lymphoma
203 Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DBLCL undergoing R-CHOP immunomunotherapy Murawski, Niels Hamburg Germany poster Aggressive Lymphomas
202 Rituximab maintenance after autologous stem cell transplantation in patients with aggressive lymphomas: Data from a multicenter prospective international registry Korfel, Agnieszka Berlin Germany poster Aggressive Lymphomas
201 Reduced intensity (FB2) vs reduced toxicity myeloablative (FB3-4) Fludarabine/busulfan based conditioning regimens for non-Hodgkin lymphoma (NHL) allografted patients. Le Bourgeois, Amandine Nantes France poster Aggressive Lymphomas
200 PROPHYLAXIS WITH HIGH-DOSE METHOTREXATE SIGNIFICANTLY REDUCES CNS DISSEMINATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND HIGH-RISK CNS-IPI SCORE Ferrier, Andrés Milano Italy poster Aggressive Lymphomas
199 R-CP chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (rPMBCL): updated results from the KEYNOTE-013 trial Zinzani, Pier Luigi Bologna Italy poster Aggressive Lymphomas
198 Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma – Report of the prospective, multicenter Phase I STORM Trial Witzans-Harg, Mathias Heidelberg Germany poster Aggressive Lymphomas
197 Rituximab, lenalidomide, and ibrutinib alone and combined with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma Westin, Jason Houston USA poster Aggressive Lymphomas
196 Double-expressor lymphomas do not have inferior outcome after autologous stem cell transplant in the first line treatment. Treny, Marek Praha Czech Republic poster Aggressive Lymphomas
195 Minimal residual disease and outcomes in relapsed/refractory follicular lymphoma (FL) in the Phase III GADOLIN trial of obinutuzumab and bendamustine vs bendamustine Pott, Christiane Kiel Germany poster Indolent Lymphoma
194 Bendamustine and rituximab improve survival in newly diagnosed mantle cell lymphoma patients: analysis of the Czech Lymphoma Study Group Obr, Aleš Olomouc Czech Republic poster Manet Cell Lymphoma
193 A Phase 2b Randomized Study of Single Agent Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Cassanoivas, Rene-Olivier Dijon France poster Aggressive Lymphomas
192 Dose-dense chemoimmunotherapy and CNS prophylaxis in patients with high-risk DLBCL: a comparison of Nordic CRY-04 and CHIC studies. Leppa, Sirpa Helsinki Finland poster Aggressive Lymphomas
191 Rituximab, lenalidomide, and ibrutinib alone and combined with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma Westin, Jason Houston USA poster Aggressive Lymphomas
190 Phase 3b study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rPMBCL): updated results from the KEYNOTE-013 trial Zinzani, Pier Luigi Bologna Italy poster Aggressive Lymphomas

14th International Conference on Malignant Lymphoma (14-ICML) June 14-17, 2017 - Lugano, Switzerland LIST OF ACCEPTED ABSTRACTS
223 A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH ADVANCED-STAGE FOLLICULAR LYMPHOMA

Buske, Christian Ulm Germany poster Indolent Lymphoma

224 Characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era

Sesséques, Pierre Paris France poster Indolent Lymphoma

225 Autologous Stem Cell Transplantation may potentially abrogate the negative prognostic effect of early relapse after chemo or immunochemotherapy in Follicular Lymphoma

Jiménez Ubieto, Ana Madrid Spain poster Indolent Lymphoma

226 "Autologous transplantation improves survival in patients with follicular lymphoma experiencing early therapy failure after frontline chemoimmunotherapy: A NLCS and CIBMTR analysis"

Casulo, Carla Rochester USA poster Indolent Lymphoma

227 Minimal residual disease (MRD) in early stage follicular lymphoma can predict prognosis and drive rituximab treatment after radiotherapy

Pulsoni, Alessandro Rome Italy poster Indolent Lymphoma

228 Low Grade B-cell Non-Hodgkin Lymphomas involving the Central Nervous System: An Analysis from the National Cancer Database

Peghali, Priyanka Rochester USA poster Indolent Lymphoma

229 Clinical characteristics and treatment outcomes for young patients with first-line follicular lymphoma: a pooled analysis of 4249 patients from the FLASH database.

Fornecker, Luc-Matthieu Strasbourg France poster Indolent Lymphoma

230 Patients with follicular lymphoma (FL) in maintained complete response (CR) at 30 months show a survival similar to a sex- and age-matched Spanish general population

Mangano, Laura Barcelona Spain poster Indolent Lymphoma

231 PDL1 and CR30 are promising surrogate endpoints for assessing the outcome of patients with advanced stage Follicular Lymphoma enrolled in the FOLL05 trial by F.I.

Luminari, Stefano Reggio Emilia Italy poster Indolent Lymphoma

232 Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FPII for multiply relapsed Follicular lymphoma in the Rituximab era

Batlev, Connie New York USA poster Indolent Lymphoma

233 Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Soumerai, Jacob New York USA poster Indolent Lymphoma

234 Statin use and prognosis in 12,865 non-Hodgkin lymphoma patients treated in the Rituximab-era

Brånvall, Elsa Stockholm Sweden poster Indolent Lymphoma

235 Ibrutinib increases the Systemic Exposure of Rituximab: Pharmacokinetic Results from the HEUROS Trial

Cramer, Paula Cologne Germany poster CLL

236 Effect of single-agent ibritinib on tumor debulking and reductions in tumor lysis syndrome (TLS) risk in patients (pts) with chronic lymphocytic leukemia (CLL)

Tam, Constantine Melbourne Australia poster CLL

237 High overall response rate with the BTK inhibitor BGB-3111 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: an update on safety and activity

Seymour, John East Melbourne Australia poster CLL

238 Long-term Efficacy and Safety in the RESONATE Study/Ibrutinib in Patients With Previously-Treated Chronic Lymphocytic Leukemia (CLL) With Up to Four Years Follow-up

Montillo, Marco Milano Italy poster CLL

239 Outcomes with Bruton Tyrosine Kinase Inhibition in relapsed / refractory chronic lymphocytic leukemia / small lymphocytic lymphoma after progression on venetoclax

Anderson, Mary Ann Melbourne Australia poster CLL

240 Outcomes of patients post-ibrutinib treatment for relapsed / Refractory CLL: A UK and Ireland analysis

Follows, George Cambridge UK poster CLL

241 Ibrutinib For Relapsed / Refractory CLL: An update of the UK And Ireland Analysis Of Outcomes In 315 Patients

Follows, George Cambridge UK poster CLL

242 Re defining the role of etoposide in peripheral T-cell lymphoma treatment

Kih, Youngil Seoul Korea, Republic of poster NK and T-cell lymphomas

243 Prognostic factors and impact of etoposide in adults with systemic ALK-positive anaplastic large-cell lymphoma: a pooled analysis of six studies

Sibon, David Paris France poster NK and T-cell lymphomas

244 Outcome of patients with relapsed and refractory peripheral T cell lymphoma intended for stem cell transplant

Parkin, Stephen Vancouver Canada poster NK and T-cell lymphomas

245 A multi-center study of GLIDE chemotherapy consolidated with autologous stem cell transplantation for newly diagnosed stage IV and relapsed extranodal natural killer/T-cell lymphoma patients

Ji, Jie Chengdu China poster NK and T-cell lymphomas

246 Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Patients with Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma (R/R-SALCL): A Retrospective Analysis of the Lymphoma Working Party-EBMT.

Domingo Domenech, Eva Barcelona Spain poster NK and T-cell lymphomas

247 Risk stratification based on NCI-IPI at the time of diagnosis in combination with post-treatment PET-CT scan for the treatment of nodal peripheral T-cell lymphoma

Yhim, Ho-Young Jeonju Korea, Republic of poster NK and T-cell lymphomas

248 The role of 18F FDG-PET/CT in peripheral T-cell lymphoma (PTCL): initial results of the UK NCRI multicentre phase II randomised CHEM0-T trial PET/CT substudy

Gleeson, Mary Sutton UK poster NK and T-cell lymphomas

249 Response by stage in CD30-positive (CD30+) cutaneous T cell lymphoma (CTCL) patients receiving brentuximab vedotin (BV) vs physician’s choice (PC) in the phase 3 ALCANZA study

Horwitz, Steven New York USA poster NK and T-cell lymphomas

250 Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the Phase 3 ALCANZA study

Prince, H. Melbourne Australia poster NK and T-cell lymphomas

251 A phase I/II study of brentuximab vedotin in pediatric patients with relapsed/refractory (R/R) systemic anaplastic large-cell lymphoma (sALCL) or R/R Hodgkin lymphoma (HL)

Locatelli, Franco Rome Italy poster NK and T-cell lymphomas

252 Prognostic factors in patients with relapsed or refractory systemic anaplastic large T-cell lymphoma (ALCL) receiving brentuximab vedotin and outcome after treatment failure.

Oki, Yashiro Houston USA poster NK and T-cell lymphomas

253 Case Match Control Analysis of PROPEL Reveals a Survival Advantage for Patients with Relapsed PTCL Receiving Prolatrexate: A Novel Approach to Benchmark Drugs in Rare Diseases

O'Connor, Owen New York USA poster NK and T-cell lymphomas
254 A Post-marketing Surveillance Study of 703 Patients Treated with Chidamide for Peripheral T-cell Lymphoma (PTCL) in China HDAC Study Group for China Lymphoma Investigators (UCU) MA, JUN Harbin China poster NK and T-cell lymphomas
255 Preliminary results from an open-label, phase II study of tipifarnib in relapsed or refractory peripheral T-cell lymphoma. Witig, Thomas Rochester USA poster NK and T-cell lymphomas
256 Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: Interim results of postmarketing all-case surveillance Ishitsuka, Kenji Kagoshima Japan poster NK and T-cell lymphomas
257 Targeting the T-cell receptor β-constant domain for immunotherapy of T-cell malignancies Macioca, Paul London UK poster NK and T-cell lymphomas
258 Development of novel, non- toxic rifamycins that reverse drug resistance in diffuse large B-cell lymphoma (DLBCL) Maxwell, Steve College Station USA poster New drug development
259 Development of novel preclinical models of secondary resistance to the PI3K inhibitor idelalisib in splenic marginal zone lymphoma (SMZL) Arrahs, Alberto Bellinzona Switzerland poster New drug development
260 Dual inhibition of EZH2 and HDAC is synergistic in EZH2 dysregulated lymphomas Lue, Jennifer New York USA poster New drug development
261 STRO-001, A NOVEL ANTI-CD74 ANTI-BODY DRUG CONJUGATE (ADC) FOR TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS (NHL) Molina, Arturo South San Francisco USA poster New drug development
262 Combinatorial screening of the PI3K inhibitor copanlisib in T cell lymphomas Gaudio, Eugenio Bellinzona Switzerland poster New drug development
263 COPANlisib in combination with anti-PD-1 induces regression in animal tumor models insensitive or resistant to the monotherapies of PI3K and checkpoint inhibitors Liu, Ningshu Berlin Germany poster New drug development
264 PD-1 immune checkpoint blockade improves anti—CD20 based immunotherapy in follicular lymphoma Rossi, Cedric Toulouse France poster New drug development
265 Novel targeted strategies to overcome microenvironment-dependent resistance in Mantle Cell Lymphoma Chiron, David Nantes France poster New drug development
266 Effective therapy by anti-CD81 against B cell lymphomas engages both direct and indirect immune mechanisms Levy, Shoshana Stanford USA poster New drug development
268 Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma Yang, Zhizhang Rochester USA poster New drug development
269 A dual targeting CAR-T-cell approach for the treatment of B cell malignancies Thomas, Simon London UK poster New drug development
270 Low Levels of Immuno-suppressor Cells Promote Responses to a Haploidentical Natural Killer Cell Therapy and Induce Remissions in Non-Hodgkin’s lymphoma Bachanova, Veronika Minneapolis USA poster New drug development
271 A phase I study of chimeric antigen receptor-modified T cells directed against CD19 in patients with relapsed or refractory CD19(+) B cell Lymphomas: interim analysis Ying, Zhtao Beijing China poster New drug development
272 Product characteristics associated with in vivo expansion of anti-CD19 CAR T-cells in patients treated with axicabtagene ciloleucel (axi-cell) Neelapu, Sattva Houston USA poster New drug development
273 Safety and Clinical Activity of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multi-center Study Carlo-Stella, Carmelo Italy poster New drug development
274 A Phase 1 Study of BET Inhibition Using RG6646 in Relapsed/Refractory (R/R) MYC-expressing Diffuse Large B Cell Lymphoma (DLBCL) Caimi, Paolo Cleveland USA poster New drug development
275 A Phase I Study of lurbinetuxib Combined with Rituximab, Ofosfamide, Carboplatin, and Etoposide in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma Sauter, Craig New York USA poster New drug development
276 Preliminary Results of a Phase 1b Study of Tributrinib (GS-4059/ONO-4059) in Combination with Entospletinib in Patients with B-cell Malignancies. Morschauser, Franck Lille France poster New drug development
277 Combination of TGR-1202, Ubituximab, and Bendamustine is Safe and Highly Active in Patients with Advanced DLBCL and Follicular Lymphoma. Luning, Matthew Omaha USA poster New drug development
278 Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-cell Lymphoma: Phase II/III Results Westin, Jason Houston USA poster New drug development
279 Ongoing Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, for the Treatment of Patients (Pts) With Relapsed/Refractory (R/R) B-Cell Malignancies (CITADEL-101) Caimi, Paolo Cleveland, OH USA poster New drug development
280 The Immunologic Doublet of Lenalidomide Plus Obinutuzumab is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase II/III Study Fowler, Nathan Houston USA poster New drug development
281 Integrated safety data with copanlisib monotherapy from phase I and II trials in patients with relapsed indolent non-Hodgkin’s lymphoma Zinzani, Pier Luigi Bologna Italy poster New drug development
282 LYMIRIT 37-01: Updated results of a phase I/II study of 11 Lu-lilotomab satetraxetan, a novel CD37-targeted antibody-radiouclide-conjugate in relapsed NHL patients Kolstad, Arne Oslo Norway poster New drug development
283 Interim Data from the First Clinical Study of ADCT-301, a Novel Pyrrolobenzodiazapine-Based Antibody Drug Conjugate, in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma Horwitz, Steve New York USA poster New drug development
284 Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory FL or DLBCL: updated results of a phase 1b/2 study Matsasar, Matthew New York, NY USA poster New drug development
285 Your Treatment Choices: Fast to Trials Programmes Radford, John Manchester UK poster New drug development
286 Increasing cross-referral and recruitment to clinical trials: a new APPROach Trotman, Judith Sydney Australia poster New drug development
287 Orol-1A (AZA) and Romidepsin (R) Reveals Promising Activity in Patients with Relapsed or Refractory (R/R) Peripheral T-cell Lymphoma (PTCL) O’Connor, Owen New York USA poster New drug development
288 CD70 expression in Cutaneous T-cell lymphoma (CTCL) patients and mechanisms of action of ARGX-110 in skin: histopathological and clinical data Hultberg, Anna Zwijnaarde Belgium poster New drug development
289 Ph 1 Trial Evaluating MRG-106, a microRNA-155 Inhibitor, Administered By Intratumoral, Subcutaneous, or Intravenous Delivery in Cutaneous T-cell Lymphoma (CTCL) Patients Queerfeld, Christiane Duarte USA poster New drug development
400 Preliminary results for a multimodality imaging approach for early detection and prediction of cardiotoxicity in doxorubicin-treated patients with malignant lymphoma
Laursen, Adam
Copenhagen Denmark
publication Aggressive Lymphomas

401 Prognostic value of Ki-67, MIPI score and SUV max of the PET SCAN: Result of a Single Center Experience with Mantle-Cell Lymphomas
Nguyen, Thuy
Brussels Belgium
publication Mantle Cell Lymphoma

402 Autologous stem cell transplantation is infrequently utilized but associated with improved overall survival in elderly patients with mantle cell lymphoma
Cohen, Jonathan
Atlanta USA
publication Mantle Cell Lymphoma

403 Short course of R-HyperCVAD/MTX/Ara-C followed by ASCT as first-line Therapy in Mantle Cell Lymphoma patients prolongs progression free survival to more than 9 years.
Andrade Campos, Marcio
Barcelona Spain
publication Mantle Cell Lymphoma

404 Improved Outcome for patients with relapsed/refractory mantle cell lymphoma (MCL) who stopibrutinib +/- rituximab for reasons other than progression of Disease
Chen, Wendy
Houston USA
publication Mantle Cell Lymphoma

405 PROGRESSION-FREE SURVIVAL SHORTENS AFTER EACH RELAPSE IN PATIENTS WITH FOLLICULAR LYMPHOMA TREATED IN THE RITUXIMAB ERA
Rivas-Delgado, Alfredo
Barcelona Spain
publication Indolent Lymphoma

406 Radioimmunotherapy for follicular lymphoma achieves excellent lymphoma control in first line and relapse: 8 year follow up data of 281 patients from the international Rit registry
Hohloch, Karin
Chur Switzerland
publication Indolent Lymphoma

407 BEYOND RITUXIMAB MAINTENANCE. RELAPSING FOLLICULAR LYMPHOMA DURING OR AFTER END OF RITUXIMAB MAINTENANCE. ANALYSIS OF CZECH LYMPHOMA STUDY GROUP (CLSG) DATABASE.
Janivova, Andrea
Brno Czech Republic
publication Indolent Lymphoma

408 Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma
Cencini, Emanuele
Siena Italy
publication Indolent Lymphoma

409 Retrospective analysis on R-DHAP/Ox and ASCT as salvage treatment for relapsed/refractory high risk follicular lymphoma.
Ghione, Paola
Torino Italy
publication Indolent Lymphoma

410 Prolonged molecular and clinical remissions in follicular lymphoma patients treated with HDI/ASCT and combination immunotherapy with rituximab and interferon a.
Benstein, Neil
Toronto Canada
publication Indolent Lymphoma

411 An international comparison of the efficacy, cost and myelotoxicity of first-line therapy for advanced follicular non-Hodgkin lymphoma
Kesavan, Murali
Perth Australia
publication Indolent Lymphoma

412 Clinical characteristics and prognosis of elderly (>70 years) follicular lymphoma in the rituximab era: multicentre retrospective analysis of the GELTAMO Spanish group
Alcoceba, Miguel
- Spain
publication Indolent Lymphoma

413 ASSESSMENT INDEX OF CLINICAL TRANSFORMATION FROM FOLLICULAR LYMPHOMA (FL) TO DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA
Shichijo, Takafumi
Tokyo Japan
publication Indolent Lymphoma

414 Risk of secondary hematological malignancy in patients with follicular lymphoma
Prusila, Roosa
Oulu Finland
publication Indolent Lymphoma

415 The prognostic value of FLIPI in the era of rituximab
Junicic, Svetiina
Ljubljana Slovenia
publication Indolent Lymphoma

416 Pretreatment soluble interleukin-2 receptor level was a robust prognostic factor in follicular lymphoma in rituximab era
Kusano, Yoshitomo
Tokyo Japan
publication Indolent Lymphoma

417 LONG-TERM FOLLOW-UP AND PREDICTORS OF POOR OUTCOME IN PATIENTS WITH FOLLICULAR LYMPHOMA UNDERGOING FRONT-LINE TREATMENT WITH CHEMOIMMUNOTHERAPY: A SINGLE CENTER EXPERIENCE.
Donato, Eva Maria
Valencia Spain
publication Indolent Lymphoma

418 Gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-Hodgkin lymphomas receiving bendamustine and rituximab
Cencini, Emanuele
Siena Italy
publication Indolent Lymphoma

419 Prognostic value of lymphocyte/monocyte ratio and neutrophil/lymphocyte ratio at diagnosis of follicular lymphoma.
Lee, Shing Fung
Hong Kong Hong Kong
publication Indolent Lymphoma

420 The value of prognostic nutritional index at diagnosis in patients with follicular lymphoma: a retrospective cohort study
Lee, Shing Fung
Hong Kong Hong Kong
publication Indolent Lymphoma

421 A retrospective study of the diagnosis and the treatment-associated mortality of patients with primary oculomucosal mucosa-associated lymphoid tissue (POMAL/MALT) lymphoma in Japan.
Masuda, Yua
Tokyo-shi Japan
publication Indolent Lymphoma

422 Clinical features and survival outcomes on lymphoplasmacytic lymphoma patients with non-igm paraproteinemia compared with igm paraproteinemia in Korea
Kang, Jihoon
Seoul Korea, Republic of
publication Indolent Lymphoma

423 PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA - THE ROLE OF MEDIASTINAL RADIATION
Alfonso, Sofia
Porto Portugal
publication Extranodal Lymphoma

424 Primary extranodal non-Hodgkin’s lymphoma of the liver (PLL).
Lepkov, Sergey
MOSCVA Russian Federation
publication Extranodal Lymphoma

425 Outcome of primary diffuse large B-cell lymphoma of the stomach – A single institute experience
Mehmoord, Tahir
Lahore Pakistan
publication Extranodal Lymphoma

426 Long-term follow-up of patients with non-Hodgkin Primary Diffuse Large B-Cell Lymphoma of the Stomach: Better outcome after immunochemotherapy
Hatijharris, Evdosia
Thessaloniki Greece
publication Extranodal Lymphoma

427 Treatment Strategies and Prognostic Factors of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Study of 303 Cases from China Lymphoma Patient Registry
Song, Yuqin
Beijing China
publication Extranodal Lymphoma

428 Clinical Features and Prognoses of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Analysis of 139 Chinese Cases with Immunophenotyping from CLAP
Song, Yuqin
Beijing China
publication Extranodal Lymphoma

429 CNS targeting chemotherapy is associated with superior survival in patients with testicular lymphoma – results from Finnish-Danish retrospective study
Mannisto, Susanna
Helsinki Finland
publication Extranodal Lymphoma

430 3D conformal radiotherapy (3D-CRT) at primary orbital lymphoma (OL) with different fractionation
Chumachenko, Anastasia
Saint-Petersburg Russian Federation
publication Extranodal Lymphoma
The effect of an immunomodulatory drug on the viability and surface molecule expression of chronic lymphocytic leukemia cells

Barna, Gábor

Karmali, Reem

Freiburghaus, Catja

Herishanu, Yair

Zhi, Rui

Liu, Hanqing

Liu, Yan-Yan

Qin, Shuchao

Xu, Wei

Nanjing

China

publication

Extranodal Lymphoma

Maliane, Maksud

Tashkent

Uzbekistan

publication

Extranodal Lymphoma

Janikova, Andrea

Brno

Czech Republic

publication

Extranodal Lymphoma

Qin, Shuchao

Nanjing

China

publication

CLL

Silva, Sofia

Lisbon

Portugal

publication

CLL

Effects on the human immune system after Obrutuzumab monotherapy treatment.

Garcia-Munoz, Ricardo

Logroño

Spain

publication

CLL

Comparison of innate immunity changes following Brutinib and Venetoclax treatment of relapsed Chronic Lymphocytic Leukaemia.

Mason, Kylie

Parkville

Australia

publication

CLL

CHRONIC LYMPHOCYTIC LEUKEMIA INVOLVEMENT OF CENTRAL NERVOUS SYSTEM: A SINGLE CENTRE EXPERIENCE

Smiljanic, Mihailo

Belgrade

Serbia

publication

CLL

Minimal residual disease assessment in multiple myeloma: Utility & feasibility in resource constraint settings of India.

Sachdeva, Man Upesh

Chandigarh

India

publication

Plasma Cell Disorders

HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT — A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP

Hus, Ioana

Lublin

Poland

publication

Plasma Cell Disorders

Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Efficacy and Safety Update (CASTOR)

Lentschzsch, Suzanne

New York, NY

USA

publication

Plasma Cell Disorders

Daratumumab, Lenalidomide, and Dexamethasome (DRd) vs Lenalidomide and Dexamethasome (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Efficacy and Safety Update (POLUX)

Bahlis, Nizar

Calgary, Alberta

Canada

publication

Plasma Cell Disorders

Barna, Gábor

Karmali, Reem

Freiburghaus, Catja

Herishanu, Yair

Zhang, Pei-Pei

Liu, Hanqing

Liu, Yan-Yan

Klener, Pavel

Xu, Wei

Waller, Allyson

Xia, Zuguang

Li, Wenyu

Guangzhou

China

publication

NK and T-cell Lymphomas

Circulating low absolute CD4+ T cell counts may predict poor prognosis in patients with extranodal NK/T-cell lymphoma, nasal type

DUSP22 and TP53 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study

Serum 2-hydroxyglutarate, a predictive biomarker of the presence of IDH2 mutations in AITL patients

The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With peripheral T-cell lymphoma

The efficacy and safety of pegaspargase, gemcitabine, dexamethasone, and cisplatin combined chemotherapy in newly diagnosed extranodal NK/T cell lymphoma

A phase II trial of Bendamustine, carboplatin and dexamethasone (BCD) for refractory or relapsed peripheral T-cell lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial

Park, Byeong-Bae

Seoul

Korea, Republic of

publication

NK and T-cell Lymphomas

Pegylated liposomal doxorubicin combined with cyclophosphamide, vincristine/vindesine, and prednisone in patients with aggressive T-cell lymphoma: preliminary results of apha II study

Xia, Zuguang

Shanghai

China

publication

NK and T-cell Lymphomas

The effect of long term maintenance chemotherapy for aggressive adult T cell leukemia/lymphoma

Tsukaguchi, Machiko

Sakai City

Japan

publication

NK and T-cell Lymphomas

Richter type T-cell large granular cell leukemia

Nakamura, Naoya

Ishihara

Japan

publication

NK and T-cell Lymphomas

Clinico-pathological profile and CMYC immunoreactivity of ALK positive Large B cell lymphoma: Report of Nine cases.

Mallick, Saumyaranjan

New Delhi

India

publication

NK and T-cell Lymphomas

Gemcitabine plus liposomal doxorubicin for relapsed refractory T-cell lymphomas

Waller, Allyson

Columbus

USA

publication

NK and T-cell Lymphomas

The efficacy and tolerance of chidamide, prednisone, cyclophosphamide and thalidomide (C-PCT) in relapsed or refractory peripheral T-cell lymphoma: a pilot study

Xu, Wei

Nanjing

China

publication

NK and T-cell Lymphomas

Established cell lines and patient-derived xenografts represent equally relevant models of aggressive lymphomas

Klierer, Pavel

Prague

Czech Republic

publication

Drugs preclinical

Constructive Expression of H2AX Predicts Better Response to Histone Deacetylase Inhibitor in Diffuse Large B-cell Lymphoma

Liu, Yan-Yan

Zhengzhou

China

publication

Drugs preclinical

Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Hodgkin Lymphoma

Szydłowski, Maciej

Warsaw

Poland

publication

Drugs preclinical

Targeting Heat Shock Protein 90 and Its Downstream Signaling Hubs for the Treatment of Mantle Cell Lymphoma

Liu, Hanqing

Zhengjiang

China

publication

Drugs preclinical

L-type Cachexia Channel Participates in Rituximab-induced Apoptosis in Diffuse Large B-cell Lymphoma

Zhang, Pei-Pei

Zhengzhong

China

publication

Drugs preclinical

MALT1 inhibition using the Small Molecule Inhibitor Mi-2 Efficiently Induces Apoptosis in CLL Cells

Hershany, Yair

Tel-Aviv

Israel

publication

Drugs preclinical

Bortezomib prevents development of cytoreantine resistance in a mantle cell lymphoma in vitro model

Freiburgauhs, Catja

Lund

Sweden

publication

Drugs preclinical

GSK-3β inhibitor, 9-ING-41 reduces cell viability and halts proliferation of B-cell Lymphoma

Karmali, Reem

Chicago

USA

publication

Drugs preclinical

Metabolic changes associated with metformin potentiates anti-Bcl-2 inhibitor, ABT-199, and CDK9 inhibitor, BAY-1143572 and reduces viability of lymphoma cells

Karmali, Reem

Chicago

USA

publication

Drugs preclinical

The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory activity towards tumor-infiltrating macrophages

Ding, Ning

Beijing

China

publication

Drugs preclinical

The effect of an immunomodulatory drug on the viability and surface molecule expression of chronic lymphocytic leukemia cells

Barna, Gabor

Budapest

Hungary

publication

Drugs preclinical

Epidemiological and humanistic burden of Cutaneous T-cell Lymphomas: results of a systematic review

### Accepted Abstracts for the 14th International Conference on Malignant Lymphomas (14-ICML)

June 14-17, 2017 - Lugano, Switzerland

LIST OF ACCEPTED ABSTRACTS
469 Molecular mechanisms and combination strategies with PI3K and BTK inhibitors to overcome intrinsic and acquired resistance in preclinical models of ABC-DLBCL
Paul, Juliane
Berlin
Germany
publication
Drugs preclinical

470 Azacytidine and Decitabine Exhibit Differential Effects on Cytotoxicity and Methylation and Exhibit Class Synergy with HDACi in Models of PTCL
Scotto, Luigi
New York
USA
publication
Drugs preclinical

471 Targeting Bcl-2 in ALK+ ALLC at the crossroads between autophagy and apoptotic cell death
Brousset, Pierre
Toulouse
France
publication
Drugs preclinical

472 A preliminary efficacy study of chidamide in combination with DICE regimen on relapsed or refractory B-cell lymphomas
Song, Yu
Beijing
China
publication
Phase I-II

473 Absence of pharmacokinetic interaction of ofatumumab and bendamustine in patients with indolent B-cell Non-Hodgkin’s Lymphoma (NHL)
Feroro-Torres, Andres
Birmingham
USA
publication
Phase I-II

474 ME-401, a Novel, Oral, Potent and Selective Inhibitor of Phosphatidylinositol 3-Kinase p110δ (PI3Kδ) in Early Clinical Development for B-cell lymphoid Malignancies
Ghalie, Richard
San Diego
USA
publication
Phase I-II

475 ONO-4059 (GS-4059), a next generation BTK inhibitor, monothersy in Patients with B-cell malignancies in the Japanese Phase 1, Dose-Escalation Study
Ando, Kiyoshi
Isahara
Japan
publication
Phase I-II

476 Pharmacokinetic analysis and clinical results of the phase 1 dose escalation and expansion CDX101 trial in relapsed, refractory lymphoma
Eyre, Toby
Oxford
UK
publication
Phase I-II

477 Safety run-in of copanlisib in combination with rituximab plus bendamustine in patients with relapsed indolent non-Hodgkin’s lymphoma
Gerecianio, John
New York
USA
publication
Phase I-II

478 Ibrutinib in Association with R-DHAP/Dx for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary results of the BIBLOS phase Ib LYSAi Study.
RONNET, Christophe
Angleur
Belgium
publication
Phase I-II

479 Engaging Administrative Data to Determine Time to Diagnosis and Treatment of Lymphoma: A Population Based Study
Skrabek, Pamela
Winnipeg
Canada
publication
Phase I-II

480 PHASE I/II STUDY OF CHOEP PLUS LENALIDOMIDE AS INITIAL THERAPY FOR PATIENTS WITH STAGE II-IV PERIPHERAL T-CELL NON-HODGKIN LYMPHOMA: PHASE I RESULTS FROM THE T-CELL CONSORTIUM
Lunning, Matthew
Omaha
USA
publication
Phase I-II

481 Dual PI3K δ/γ Inhibitor RP6530 in Patients with Relapsed/Refractory T-cell Lymphoma: Dose Escalation Findings.
Oki, Yasuhiro
Houston
USA
publication
Phase I-II

482 PICL-related thrombosis in patients with aggressive lymphoma treated with DA-EPOCH – how to prevent it?
Mitrovic, Zdravko
Zagreb
Croatia
publication
Miscellaneous

483 High Rate of Morbid Central Line Associated Complications During Treatment with Dose-Adjusted R-EPOCH Therapy for Non-Hodgkin Lymphoma.
Reagan, Patrick
Rochester
USA
publication
Miscellaneous

484 Subcutaneous Rituximab in B-cell non-Hodgkin Lymphoma: a single-center experience
Sanchez-Gonzalez, Blanca
Barcelona
Spain
publication
Miscellaneous

485 PHARMOVIGILANCE OF RITUXIMAB BIOSIMILAR IN THE TREATMENT OF LYMPHOMAS IN ARGENTINA
Milone, Gustavo
Buenos Aires
Argentina
publication
Miscellaneous

486 Real-life use of bendamustine for B-cell non-Hodgkin Lymphoma in a community hospital in Japan – retreatment with bendamustine is safe and feasible –
Matsuki, Eri
Tokyo
Japan
publication
Miscellaneous

487 Thalidomide in relapsed lymphoma: 5 years of experience from Southend University Hospital NHS Foundation Trust
Blacker, Edward
Southend
UK
publication
Miscellaneous

488 Comparative analysis of predictive models for thromboembolic events in lymphoma patients
Artic, Darko
Belgrade
Serbia
publication
Miscellaneous

489 Incidence and Survival of Non-Hodgkin Lymphoma at Oncosalud -AUNA: A Dynamic Cohort Study
Flores, Claudio J.
Lima
Peru
publication
Miscellaneous

490 Longerhans cell histiocytosis in adults is associated with increased hematologic and solid malignancies
Ma, Jennifer
New York
USA
publication
Miscellaneous

491 A prospective study to evaluate the utility of geriatric assessment and intervention in patients with lymphoproliferative disorders in a tertiary hospital
Bastos-Oreiro, Mariana
Madrid
Spain
publication
Miscellaneous

OT07 Phase I/I study of Brentuximab Vedotin in refractory/relapsed Hodgkin lymphoma patients treated by chemotherapy (ICE) in second line before autologous transplantation
Stamatoulias, Aspasia
Rouen
France
publication
Ongoing trials

OT08 A Phase 1/2 study of pixantrone, etoposide, bendamustine and, in CD20+ tumors, rituximab in patients with relapsed aggressive B- or T-cell lymphomas – The PR[E]BE.N study
D’Amore, Francesco
Aarhus C
Denmark
publication
Ongoing trials

OT09 DEVEC: A PHASE II STUDY OF METRONOMIC CHEMOTHERAPY IN ELDERLY NON-FIT PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMAS (promoted by F.I.L.)
COX, M CHRISTINA
ROMA
Italy
publication
Ongoing trials

OT10 PLECT-GUIDED BIOPSY FOR THE DIAGNOSIS OF LYMPHOMA
Broccoli, Alessandro
Bologna
Italy
publication
Ongoing trials

OT11 FiL-PTCL13: Phase Ib/II Study of Romidepsin/CHOEP Followed by High-Dose Chemotherapy and Transplantation in Untreated Peripheral T-cell Lymphomas.
Chiappella, Annalisa
Torino
Italy
publication
Ongoing trials

OT12 A MRD-guided approach for the combination of ibrutinib to venetoclax in relapsed/refractory patients with chronic lymphocytic leukemia (IMPROVE study)
Ghia, Paolo
Milano
Italy
publication
Ongoing trials

OT13 Phase 3 Study of Ibrutinib in Combination With Rituximab Versus Placebo in Combination With Rituximab in Patients With Treatment-Naive follicular Lymphomas (PERSPECTIVE)
Rule, Simon
Plymouth
UK
publication
Ongoing trials

OT14 An ongoing phase 2 study of ibrutinib combined with venetoclax in patients with treatment-naive CLL/SLL
Ghia, Paolo
Milan
Italy
publication
Ongoing trials